New Study Supports Potential Utility of ChemoFx in Primary Ovarian Cancer

PITTSBURGH--()--A new study that looks at the synergy between ChemoFx® in vitro drug response marker results for non-platinum single agents alone and in combination with carboplatin was presented at the International Gynecologic Cancer Society (IGCS) Annual Meeting, which was held in Vancouver October 13-16, 2012.

Dr. Dennis Scribner presented the abstract, titled, Does In-Vitro Chemosensitivity Show Synergy When Comparing Single Agents to Platinum-Based Combinations in Ovarian Cancer. The study, performed in cooperation with Virginia Tech Carilion School of Medicine, analyzed primary ovarian cancer specimens for patterns of response to platinum and non-platinum based therapies, using the ChemoFx® Drug Response Marker. The investigation was implemented to observe synergy in drug sensitivity between single agents and combination agents in vitro.

The data analyzed trends between single agents versus doublet therapies. In vitro response rates were found to mirror clinical data, which showed that response to doublet therapy is significantly higher compared to single agents, and increased chemosensitivity for single agents aligned with increased chemosensitivity to doublet therapy containing that agent. This information supports the potential utility of ChemoFx testing in personalizing chemotherapy regimens for ovarian cancer patients.

“Because gynecological cancers can be extremely difficult to treat, having information on the synergy between single and combination agents in vitro can be very useful when selecting treatment tailored to a patient,” says Dr. Scribner, lead author of the study. “This promising data further examines the utility of ChemoFx results in understanding the patterns of response to platinum and non-platinum based therapies.”

About Precision Therapeutics

Precision Therapeutics, a leading life-science company based in Pittsburgh, Pennsylvania, is dedicated to personalized cancer care. Precision offers a portfolio of products developed to help guide physicians and patients with difficult clinical decisions throughout the cancer care continuum.

Precision's state of the art Comprehensive Tumor Profiling is an integrated, straightforward approach combining three core platforms of personalized medicine to capture the total sum of genomic, proteomic and functional information for each patient's cancer.

Precision's first commercial test, ChemoFx®, is a proprietary drug response marker which measures an individual's malignant tumor response to a range of standard therapeutic alternatives under consideration by a physician. Precision currently receives ChemoFx® specimens from 271 top medical institutions including 20 of the 21 National Comprehensive Cancer Network (NCCN) Member Institutions, and 8 of the US News and World Report Top 10 Hospitals for Cancer Care. To date, approximately 80,000 patient specimens have been submitted for ChemoFx® testing using 105 unique chemotherapy treatments and combinations. For more information, visit: www.precisiontherapeutics.com or www.chemofx.com.

Contacts

Precision Therapeutics Inc.
Pam Ranallo, 412-432-1500 ext. 1502
pranallo@ptilabs.com

Sharing

Contacts

Precision Therapeutics Inc.
Pam Ranallo, 412-432-1500 ext. 1502
pranallo@ptilabs.com